OncoMatch/Clinical Trials/NCT04716452
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Is NCT04716452 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Ceramide NanoLiposome (Ceraxa) for acute myeloid leukemia, in relapse.
Treatment: Ceramide NanoLiposome (Ceraxa) — The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
Creatinine clearance > 60 mL/min
Liver function
Total bilirubin ≤ 1.5 × ULN or < 3 x ULN for patients with Gilbert-Meulengracht Syndrome; AST and ALT ≤ 3 × ULN if not attributed to leukemia, or ≤ 5 x ULN if attributed to leukemia
Adequate organ function as evidenced by the following laboratory findings: * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) or < 3 x ULN for patients with Gilbert-Meulengracht Syndrome * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN if not attributed to leukemia, or ≤ 5 x ULN if attributed to leukemia * Creatinine clearance > 60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia Cancer Center · Charlottesville, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify